Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has provided an announcement.
CANbridge Pharmaceuticals Inc. has entered into three subscription agreements to issue nearly 10 million new shares at a discounted price of HK$2.26 each, raising gross proceeds of approximately HK$22.59 million. The net proceeds will be used for research and development of existing products and daily operations, potentially strengthening the company’s financial position and enhancing its ability to innovate in the biopharmaceutical industry.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases and targeted cancers. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 14,575,128
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.32B
See more data about 1228 stock on TipRanks’ Stock Analysis page.